Logo image of ALSGD.PA

SPINEGUARD SA (ALSGD.PA) Stock Fundamental Analysis

Europe - EPA:ALSGD - FR0011464452 - Common Stock

0.1388 EUR
+0 (+1.91%)
Last: 10/20/2025, 7:00:00 PM
Fundamental Rating

1

Taking everything into account, ALSGD scores 1 out of 10 in our fundamental rating. ALSGD was compared to 59 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ALSGD have multiple concerns. ALSGD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALSGD had negative earnings in the past year.
In the past year ALSGD has reported a negative cash flow from operations.
In the past 5 years ALSGD always reported negative net income.
In the past 5 years ALSGD always reported negative operating cash flow.
ALSGD.PA Yearly Net Income VS EBIT VS OCF VS FCFALSGD.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M -4M

1.2 Ratios

ALSGD's Return On Assets of -30.69% is on the low side compared to the rest of the industry. ALSGD is outperformed by 83.05% of its industry peers.
ALSGD's Return On Equity of -59.82% is on the low side compared to the rest of the industry. ALSGD is outperformed by 77.97% of its industry peers.
Industry RankSector Rank
ROA -30.69%
ROE -59.82%
ROIC N/A
ROA(3y)-32.05%
ROA(5y)-28.87%
ROE(3y)-64.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALSGD.PA Yearly ROA, ROE, ROICALSGD.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

With an excellent Gross Margin value of 70.98%, ALSGD belongs to the best of the industry, outperforming 81.36% of the companies in the same industry.
ALSGD's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ALSGD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5Y-2.09%
ALSGD.PA Yearly Profit, Operating, Gross MarginsALSGD.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

1

2. Health

2.1 Basic Checks

ALSGD does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALSGD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALSGD has been increased compared to 5 years ago.
Compared to 1 year ago, ALSGD has a worse debt to assets ratio.
ALSGD.PA Yearly Shares OutstandingALSGD.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALSGD.PA Yearly Total Debt VS Total AssetsALSGD.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

ALSGD has an Altman-Z score of -3.40. This is a bad value and indicates that ALSGD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ALSGD (-3.40) is worse than 89.83% of its industry peers.
ALSGD has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ALSGD (0.34) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z -3.4
ROIC/WACCN/A
WACC8.22%
ALSGD.PA Yearly LT Debt VS Equity VS FCFALSGD.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M

2.3 Liquidity

ALSGD has a Current Ratio of 1.07. This is a normal value and indicates that ALSGD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.07, ALSGD is doing worse than 74.58% of the companies in the same industry.
ALSGD has a Quick Ratio of 1.07. This is a bad value and indicates that ALSGD is not financially healthy enough and could expect problems in meeting its short term obligations.
ALSGD has a Quick ratio of 0.82. This is in the lower half of the industry: ALSGD underperforms 64.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 0.82
ALSGD.PA Yearly Current Assets VS Current LiabilitesALSGD.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.66% over the past year.
Looking at the last year, ALSGD shows a decrease in Revenue. The Revenue has decreased by -4.47% in the last year.
Measured over the past years, ALSGD shows a decrease in Revenue. The Revenue has been decreasing by -7.41% on average per year.
EPS 1Y (TTM)47.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.37%
Revenue 1Y (TTM)-4.47%
Revenue growth 3Y1.8%
Revenue growth 5Y-7.41%
Sales Q2Q%-13.31%

3.2 Future

ALSGD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.42% yearly.
The Revenue is expected to grow by 1.70% on average over the next years.
EPS Next Y83.22%
EPS Next 2Y35.36%
EPS Next 3Y29.42%
EPS Next 5YN/A
Revenue Next Year-15.4%
Revenue Next 2Y-7.32%
Revenue Next 3Y1.7%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALSGD.PA Yearly Revenue VS EstimatesALSGD.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
ALSGD.PA Yearly EPS VS EstimatesALSGD.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALSGD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALSGD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSGD.PA Price Earnings VS Forward Price EarningsALSGD.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSGD.PA Per share dataALSGD.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 -0.04 0.06

4.3 Compensation for Growth

ALSGD's earnings are expected to grow with 29.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.36%
EPS Next 3Y29.42%

More info and screens

0

5. Dividend

5.1 Amount

ALSGD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPINEGUARD SA

EPA:ALSGD (10/20/2025, 7:00:00 PM)

0.1388

+0 (+1.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-09 2025-10-09
Earnings (Next)04-13 2026-04-13
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap8.75M
Analysts84.44
Price Target0.64 (361.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)79.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-23.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.02
P/FCF N/A
P/OCF N/A
P/B 2.04
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.07
BVpS0.07
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.69%
ROE -59.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.98%
FCFM N/A
ROA(3y)-32.05%
ROA(5y)-28.87%
ROE(3y)-64.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5Y-2.09%
F-Score4
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.97%
Cap/Sales 5.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 0.82
Altman-Z -3.4
F-Score4
WACC8.22%
ROIC/WACCN/A
Cap/Depr(3y)225.04%
Cap/Depr(5y)170.18%
Cap/Sales(3y)14.39%
Cap/Sales(5y)11.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.37%
EPS Next Y83.22%
EPS Next 2Y35.36%
EPS Next 3Y29.42%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.47%
Revenue growth 3Y1.8%
Revenue growth 5Y-7.41%
Sales Q2Q%-13.31%
Revenue Next Year-15.4%
Revenue Next 2Y-7.32%
Revenue Next 3Y1.7%
Revenue Next 5YN/A
EBIT growth 1Y43.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.56%
EBIT Next 3Y31.68%
EBIT Next 5YN/A
FCF growth 1Y65.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.57%
OCF growth 3YN/A
OCF growth 5YN/A